SO THE US RETT STUDY (1) IS ACTUALLY 12 WEEKS AND NOT 7?
DOES THE BELOW ONLY APPLY TO THE AVATAR STUDY DESPITE IT CLAIMING OTHERWISE?
To offer all participants access to ANAVEX®2-73 (blarcamesine) after completion of the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett syndrome study[1] and the AVATAR Rett syndrome study[2], 12-week and 48-week open-label extension studies, respectively were initiated. Currently 90% and 100% of eligible participants have continued into the corresponding extension studies.
IT'S REAL CONFUSING WHEN AVXL'S OWN PR'S CONTRADICT THEMSELVES!!!!